These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 25579119)

  • 1. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
    Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
    Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
    Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
    Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of microRNAs in drug-resistant ovarian cancer cells.
    Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
    Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
    Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
    Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
    Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
    Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
    Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines].
    Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
    Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
    Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
    Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
    J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
    Niu L; Ni H; Hou Y; Du Q; Li H
    Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
    Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
    Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
    Xu ZH; Yao TZ; Liu W
    Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
    Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
    Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.